Investment Rating - The report assigns an "Accumulate-A" investment rating to the company with a target price of 30.19 CNY for the next six months [3]. Core Insights - Chengda Biological has established itself as a leader in the rabies vaccine market, maintaining a dominant position for over a decade. The company's growth is expected to be driven by three main factors: increasing market share of existing products, commercialization of its research pipeline, and the strategic initiatives following the indirect control by Guangdong Min Investment [1][7]. - The company has a robust product matrix, with its rabies vaccine and inactivated Japanese encephalitis vaccine being the primary revenue sources. Recent years have seen performance pressures due to intensified competition [2][24]. - The research pipeline is rich, with several vaccines, including the human diploid rabies vaccine and quadrivalent influenza vaccine, set for registration applications in the coming years [3][21]. Summary by Sections 1. Company Overview - Chengda Biological has been focused on the vaccine sector for over 20 years, with its core product, the human rabies vaccine, launched in 2005. The company has maintained a leading market share since 2008 [1][13]. - The company also offers the only inactivated Japanese encephalitis vaccine available in China, which has seen significant marketing efforts to enhance its market penetration [2][24]. 2. Product Matrix - The rabies vaccine produced using Vero cells is the leading product, with a stable and efficient production process. The company has also initiated the application for the human diploid rabies vaccine [2][41]. - The inactivated Japanese encephalitis vaccine has been upgraded and is expected to see significant growth from 2022 to 2024 due to increased academic promotion and brand awareness [2][24]. 3. Research Pipeline - The company has a well-stocked research pipeline, with multiple vaccines in various stages of development, including the human diploid rabies vaccine and several influenza vaccines [3][21]. - The 15-valent HPV vaccine is set to enter Phase II clinical trials in March 2025, while other vaccines are progressing through different clinical trial phases [3][21]. 4. Shareholder Empowerment - The governance structure of Chengda Biological has been significantly enhanced following the indirect control by Guangdong Min Investment, which is expected to facilitate innovation and investment opportunities [7][15]. - The company has announced several investment initiatives, including the establishment of a wholly-owned subsidiary for innovative drugs and a biopharmaceutical investment fund, aiming to create a dual-driven business model of "vaccines + innovative drugs" [7][8]. 5. Financial Forecast and Valuation - The company is projected to achieve revenues of 1.39 billion CNY, 1.48 billion CNY, and 1.59 billion CNY for the years 2025, 2026, and 2027, respectively, with net profits of 131 million CNY, 141 million CNY, and 177 million CNY [8][9].

[Table_scodeMsg1] 公司研究丨深度报告丨建投能源（000600.SZ） [Table_Title] 建投能源：冀电龙头，擎势腾飞 %% %% 请阅读最后评级说明和重要声明 2 / 28 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 复盘主要火电公司的表现，2025 年火电投资呈现出"北移"和看重业绩释放的特征，建投能源 盈利的持续修复驱动公司股价表现优异。聚焦公司火电经营，公司深耕河北地区，区域电源结 构支撑公司具备优于行业的电价韧性，构筑起公司强大的区域护城河；而展望来看河北区域电 力供需预计将保持紧平衡，为公司保持电价相对优势提供强有力支撑。此外，公司在建及储备 项目丰厚，参控股火电机组投产后预计将为公司带来 34%的权益装机成长空间，2026 年公司 将步入明确的成长兑现期。 分析师及联系人 [Table_Author] 张韦华 司旗 宋尚骞 SAC：S0490517080003 SAC：S0490520120001 SAC：S0490520110001 SFC：BQT627 刘亚辉 张子淳 SAC：S049 ...

2026 年 02 月 05 日 公司业绩表现亮眼，AI 算力硬件与 AI 算力服务 业务双轮驱动 买入(首次) 事件 分析师：何鹏程 S1050525070002 hepc@cfsc.com.cn 联系人：石俊烨 S1050125060011 shijy@cfsc.com.cn 2025 年，谷歌 Token 日均调用量达到 16 万亿，较 2024 年同 期增长 50 倍；Azure AI 一季度处理 Token 数较 2024 年同期 增长 5 倍；2025 年 5 月，字节火山引擎 Token 日均调用量是 2024 年同期的 137 倍。 | 基本数据 | 2026-02-04 | | --- | --- | | 当前股价（元） | 205.85 | | 总市值（亿元） | 712 | | 总股本（百万股） | 346 | | 流通股本（百万股） | 345 | | 52 周价格范围（元） | 71.28-231.68 | | 日均成交额（百万元） | 1719.5 | 市场表现 -50 0 50 100 150 200 250 300 (%) 协创数据 沪深300 资料来源：Wind，华鑫证券研究 ...

市场表现 -50 0 50 100 150 200 250 300 (%) 协创数据 沪深300 资料来源：Wind，华鑫证券研究 2026 年 02 月 05 日 公司业绩表现亮眼，AI 算力硬件与 AI 算力服务 业务双轮驱动 买入(首次) 事件 分析师：何鹏程 S1050525070002 hepc@cfsc.com.cn 联系人：石俊烨 S1050125060011 shijy@cfsc.com.cn | 基本数据 | 2026-02-04 | | --- | --- | | 当前股价（元） | 205.85 | | 总市值（亿元） | 712 | | 总股本（百万股） | 346 | | 流通股本（百万股） | 345 | | 52 周价格范围（元） | 71.28-231.68 | | 日均成交额（百万元） | 1719.5 | 相关研究 —协创数据（300857.SZ）公司事件点评报告 协创数据发布业绩公告：预计 2025 年实现归母净利润 10.5 亿 元至 12.5 亿元，同比增长 51.78%至 80.69%%；实现扣非净利 润 10.1 亿元至 12.1 亿元，同比增长 50.45%至 ...

丨证券研究报告丨 张韦华 司旗 宋尚骞 刘亚辉 张子淳 [Table_scodeMsg1] 公司研究丨点评报告丨大唐发电（601991.SH） [Table_Title] 单季经营延续改善，全年业绩弹性释放 报告要点 [Table_Summary] 2025 年公司实现上网电量 2731.09 亿千瓦时，同比增长 1.41%，其中第四季度公司完成上网 电量 668.68 亿千瓦时，同比微降 0.50%。电价方面，2025 年公司平均上网电价约为 0.435 元 /千瓦时，同比降低约 0.017 元/千瓦时。在燃料成本仍同比改善的带动下，四季度公司主业经营 延续改善趋势，公司预计 2025 年实现归母净利润 68 亿元到 78 亿元，同比增加 51%到 73%； 四季度公司预计实现归母净利润 0.88 亿元到 10.88 亿元，同比增加 14%到 1317%。 分析师及联系人 [Table_Author] SAC：S0490517080003 SAC：S0490520120001 SAC：S0490520110001 SAC：S0490523080003 SFC：BQT627 请阅读最后评级说明和重要声明 %% ...

Investment Rating - The report assigns an "Accumulate" rating for the company [1]. Core Insights - The company focuses on high-precision intelligent dispensing equipment and has established a strong position in the supply chain for Apple products, while also expanding into new applications such as Meta AI glasses and semiconductors [3][5]. - The global dispensing machine market is expected to reach USD 10.68 billion by 2028, indicating significant growth potential in downstream applications [4]. - The company reported a net profit of CNY 40.69 million in Q1-Q3 2025, representing a year-on-year increase of 366.01% [3]. Financial Summary and Valuation Metrics - Revenue projections for the company are as follows: - 2025E: CNY 3.34 billion (up 167.1% YoY) - 2026E: CNY 3.79 billion (up 13.5% YoY) - 2027E: CNY 4.22 billion (up 11.2% YoY) [7]. - Net profit forecasts are: - 2025E: CNY 530 million - 2026E: CNY 620 million - 2027E: CNY 720 million [3]. - The company's EPS for the next three years is projected to be CNY 0.65, CNY 0.76, and CNY 0.88, with corresponding PE ratios of 59.7, 51.3, and 44.0 [3][7]. Market Position and Competitive Advantage - The company has developed its dispensing valve products to achieve industry-leading performance in consistency error and operational frequency, surpassing competitors like Nordson and Musashi [29][30]. - The company has established stable partnerships with major EMS manufacturers and equipment integrators in the Apple supply chain, enhancing its market position [47][49]. - The company has successfully entered the supply chain of CATL and obtained vendor codes from Samsung Electronics, further strengthening its competitive edge [5].

Investment Rating - The report maintains a "Recommend" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [7][13]. Core Insights - Yutong Technology (002831) is positioned as a leading player in the packaging industry, benefiting from stable growth and high dividend payouts. The company is expected to gain from the development of its smart glasses business [2][7]. - The company holds a 0.48% stake in Longqi Technology, which recently listed on the Hong Kong Stock Exchange, potentially enhancing collaboration in the smart glasses sector [2][7]. - Yutong's overseas production capacity provides a significant competitive advantage, with higher gross margins in international markets compared to domestic ones. The gross margin for overseas markets was 28.79% in the first half of 2025, while domestic margins were only 19.41% [2][7]. Financial Summary - Projected total revenue (in million) for the years 2024 to 2027 is as follows: - 2024: 17,157 - 2025: 18,818 - 2026: 20,907 - 2027: 22,922 - Year-on-year revenue growth rates are projected at 12.7% for 2024, 9.7% for 2025, 11.1% for 2026, and 9.6% for 2027 [2][8]. - Projected net profit (in million) for the same period is: - 2024: 1,409 - 2025: 1,643 - 2026: 1,902 - 2027: 2,172 - Year-on-year net profit growth rates are expected to be -2.1% for 2024, 16.6% for 2025, 15.8% for 2026, and 14.2% for 2027 [2][8]. - The target price for the stock is set at 35.13 CNY, with the current price at 30.01 CNY [3][7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market by more than 15% over the next 12 months [7]. Core Insights - The company reported a stable performance in 2025, with revenue increasing by 0.5% year-on-year to RMB 14.72 billion, and net profit attributable to shareholders increasing by 10.4% to RMB 1.23 billion, aligning with market expectations [7]. - The company demonstrated resilience in operations, maintaining stable sales volume and pricing despite a challenging market environment characterized by weak demand and low restaurant consumption [7]. - The introduction of new products and a potential recovery in the restaurant sector in 2026 are seen as opportunities for growth [7]. Financial Summary - **Revenue Forecast**: - 2023A: RMB 14,815 million - 2024A: RMB 14,645 million - 2025E: RMB 14,722 million - 2026E: RMB 15,098 million - 2027E: RMB 15,521 million - Growth Rate: 5.5% (2023A), -1.1% (2024A), 0.5% (2025E), 2.6% (2026E), 2.8% (2027E) [3][11] - **Net Profit Forecast**: - 2023A: RMB 1,337 million - 2024A: RMB 1,115 million - 2025E: RMB 1,231 million - 2026E: RMB 1,295 million - 2027E: RMB 1,366 million - Growth Rate: 5.8% (2023A), -16.6% (2024A), 10.4% (2025E), 5.2% (2026E), 5.4% (2027E) [3][11] - **Earnings Per Share (EPS)**: - 2023A: RMB 2.76 - 2024A: RMB 2.30 - 2025E: RMB 2.54 - 2026E: RMB 2.68 - 2027E: RMB 2.82 [3][11] - **Valuation Ratios**: - Price-to-Earnings (P/E) Ratio: 24.1 (2023A), 27.4 (2024A), 21.4 (2025E), 20.3 (2026E), 19.3 (2027E) [3][11] - Return on Equity (ROE): 62.5% (2023A), 94.0% (2024A), 103.9% (2025E), 109.3% (2026E), 115.2% (2027E) [3][11] - EV/EBITDA: 7.7 (2023A), 7.9 (2024A), 6.4 (2025E), 5.8 (2026E), 5.2 (2027E) [3][11]

Investment Rating - The report maintains a "Recommend" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [7][13]. Core Insights - Yutong Technology (002831) is positioned as a leading player in the packaging industry, benefiting from stable growth and high dividend payouts. The company is expected to gain from the development of its smart glasses business [2][7]. - The company holds a 0.48% stake in Longqi Technology, which recently listed on the Hong Kong Stock Exchange, potentially enhancing collaboration in the smart glasses sector [2][7]. - Yutong's overseas production capacity provides a significant competitive advantage, with higher gross margins in international markets compared to domestic ones. The gross margin for overseas markets was 28.79% in the first half of 2025, while domestic margins were only 19.41% [2][7]. - The company is projected to achieve steady revenue growth, with total revenue expected to reach 17.16 billion yuan in 2024, growing to 22.92 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 9.6% [2][8]. - Net profit attributable to the parent company is forecasted to increase from 1.41 billion yuan in 2024 to 2.17 billion yuan in 2027, with a notable growth rate of 16.6% in 2025 [2][8]. - The target price for the company's stock is set at 35.13 yuan, based on a price-to-earnings (P/E) ratio of 17 times for 2026 [3][7]. Financial Summary - Total revenue projections for Yutong Technology are as follows: - 2024: 17,157 million yuan - 2025: 18,818 million yuan - 2026: 20,907 million yuan - 2027: 22,922 million yuan - Net profit attributable to the parent company is projected as: - 2024: 1,409 million yuan - 2025: 1,643 million yuan - 2026: 1,902 million yuan - 2027: 2,172 million yuan - Earnings per share (EPS) is expected to grow from 1.53 yuan in 2024 to 2.36 yuan in 2027 [2][8].

Investment Rating - The report maintains a "Strong Buy" rating for Chongqing Beer, expecting it to outperform the benchmark index by over 20% in the next six months [2][22]. Core Views - The company demonstrated resilience in its operations, with a slight revenue increase of 0.5% year-on-year to CNY 14.72 billion in 2025, and a net profit growth of 10.4% to CNY 1.23 billion [2][3]. - The report highlights the company's strategic focus on expanding non-traditional sales channels, such as instant retail and e-commerce, which contributed to stable revenue and sales performance despite challenges in the dining sector [2][3]. - The company is expected to continue its high dividend strategy, with a projected dividend yield of 4.7% based on a 100% payout ratio, providing a solid margin of safety for investors [2][3]. Financial Performance Summary - **Revenue and Profitability**: In 2025, the company achieved total revenue of CNY 14.72 billion, with a net profit of CNY 1.23 billion. The earnings per share (EPS) for 2025 is projected at CNY 2.54, with a price-to-earnings (P/E) ratio of 21 [2][3][11]. - **Cost Management**: The gross margin improved due to cost benefits and product mix upgrades, despite increased marketing expenses aimed at consolidating market presence [2][3]. - **Future Projections**: The report adjusts the earnings forecast for 2025-2027 to CNY 1.23 billion, CNY 1.31 billion, and CNY 1.39 billion respectively, reflecting a positive outlook for continued profit growth [2][3][11]. Market Position and Strategy - The company is focusing on high-end product lines, which are expected to drive growth, alongside the recovery of dining scenarios that will support revenue increases [2][3]. - The report emphasizes the importance of new product launches and collaborations with platforms like JD.com to capture additional market share [2][3]. Valuation Metrics - The target price for Chongqing Beer is set at CNY 67, which corresponds to a P/E ratio of approximately 25 times for 2026 earnings [3][11]. - The current market price is CNY 54.40, indicating potential upside for investors [3]. Conclusion - The report concludes that despite challenges, Chongqing Beer is well-positioned for growth with a strong dividend policy and strategic initiatives aimed at expanding its market presence [2][3].